Bright Reconciled Depreciation from 2010 to 2024

DRUG Stock  USD 44.00  4.82  12.30%   
Bright Minds' Reconciled Depreciation is increasing over the last several years with slightly volatile swings. Reconciled Depreciation is estimated to finish at about 87.5 K this year. During the period from 2010 to 2024 Bright Minds Biosciences Reconciled Depreciation regressed destribution of quarterly values had coefficient of variationof  201.74 and r-value of  0.71. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2010-12-31
Previous Quarter
83.3 K
Current Value
87.5 K
Quarterly Volatility
33.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bright Minds financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bright Minds' main balance sheet or income statement drivers, such as Depreciation And Amortization of 51.8 K, Interest Expense of 21.6 K or Selling General Administrative of 1.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.32. Bright financial statements analysis is a perfect complement when working with Bright Minds Valuation or Volatility modules.
  
Check out the analysis of Bright Minds Correlation against competitors.

Latest Bright Minds' Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Bright Minds Biosciences over the last few years. It is Bright Minds' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bright Minds' overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

Bright Reconciled Depreciation Regression Statistics

Arithmetic Mean16,619
Geometric Mean0.00
Coefficient Of Variation201.74
Mean Deviation25,786
Median0.00
Standard Deviation33,528
Sample Variance1.1B
Range87.5K
R-Value0.71
Mean Square Error593.5M
R-Squared0.51
Significance0
Slope5,352
Total Sum of Squares15.7B

Bright Reconciled Depreciation History

202487.5 K
202383.3 K
202272.5 K
2021 6037.0

About Bright Minds Financial Statements

Bright Minds stakeholders use historical fundamental indicators, such as Bright Minds' Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Although Bright Minds investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bright Minds' assets and liabilities are reflected in the revenues and expenses on Bright Minds' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bright Minds Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation83.3 K87.5 K

Currently Active Assets on Macroaxis

When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:
Check out the analysis of Bright Minds Correlation against competitors.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.63)
Return On Assets
(0.29)
Return On Equity
(0.52)
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.